|
|
Upfront Briefing
FDA greenlit Lilly’s oral obesity pill orforglipron (Foundayo), pushing the GLP-1 arms race from injections into “pop-a-pill” territory.
Elsewhere: STAT says draft 100% tariffs could land on some imported drugs, while Gilead ended a Phase 2/3 long-acting HIV pill trial with a clinical hold still in place (the fastest way to shrink optionality).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,575.3 |
+0.7% |
(4.1%) |
| Nasdaq 100 |
24,020.0 |
+1.2% |
(4.7%) |
| Russell 2000 |
2,512.4 |
+0.6% |
+0.2% |
| Healthcare (XLV) |
147.7 |
+0.8% |
(4.6%) |
| Biotech (XBI) |
128.6 |
+0.6% |
+5.8% |
| Nasdaq Biotech (NBI) |
5,874.3 |
+0.6% |
+2.9% |
| Clinical Trials (BBC) |
42.4 |
+1.9% |
+12.7% |
|
- Risk-on rebound: the Nasdaq 100 (+1.2%) led as hopes of a near-term Iran de-escalation pushed oil lower and reopened room for growth after last week’s energy/inflation scare.
- Healthcare kept pace rather than lagging: XLV (+0.8%) rose with the broader tape, while biotech stayed constructive with XBI (+0.6%) / NBI (+0.6%) as dealflow and Lilly’s Foundayo approval reinforced the “innovation + scarcity value” bid.
- Market data: U.S. close Wed 01-Apr-2026.
The Big 3
|
1
|
FDA approves Lilly oral obesity pill orforglipron
|
- FDA approved Lilly’s oral obesity pill orforglipron (Foundayo), a once-daily small-molecule GLP-1 that can be taken without food or water restrictions. In Phase 3 obesity studies, patients at the highest dose lost an average of 12.4% of body weight at 72 weeks among treatment completers, with broader-program weight loss around 11.1% regardless of trial completion.
- Why it matters: This is the first real scale test of whether a convenient oral GLP-1 can materially expand the treated obesity pool beyond injection-tolerant patients. For investors, the key question is not just pill versus shot efficacy; it is whether simpler dosing, lower manufacturing complexity, and broader access channels let Lilly win incremental starts and persistence even if injectables still lead on absolute weight loss. That makes Foundayo important both as a new revenue leg and as a signal that the obesity market may segment by convenience, adherence, and payer economics rather than a single efficacy leaderboard.
- Source: BioPharma Dive
- More: BioSpace
|
|
2
|
Trump team drafts 100% tariffs on some imported drugs
|
- STAT reports the Trump administration has prepared a draft order that would impose 100% tariffs on some imported patented drugs and active ingredients, with carve-outs or exemptions still possible.
- Why it matters: For investors this is less a “drug pricing” headline than a gross-margin and capital-allocation scenario analysis. If implemented, the biggest exposure would sit with import-reliant branded products and companies without enough U.S. manufacturing or negotiated exemptions. The first-order hit is COGS; the second-order hit is strategic, as management teams may be forced into faster onshoring, dual-sourcing, inventory buffers, or pricing resets. Until the final structure is clear, the right framing is optionality compression for exposed franchises rather than immediate earnings destruction.
- Source: STAT
|
|
3
|
Gilead ends Phase 2/3 long-acting HIV pill trial after hold
|
- Gilead ended the Phase 2/3 WONDERS-2 trial of weekly oral GS-1720 plus GS-4182 while the FDA clinical hold remains in place. The regimen had been positioned as a next-gen long-acting oral challenger to daily standards including Biktarvy.
- Why it matters: This is a pipeline setback in HIV, not a routine study-management decision. GS-1720/GS-4182 had been one of Gilead’s more differentiated attempts to extend the franchise beyond current daily oral therapy. With WONDERS-2 terminated and the clinical hold still in place, investors lose one longer-dated option for franchise renewal and are pushed back toward Gilead’s nearer-term HIV defenses and remaining lenacapavir-based life-cycle paths.
- Source: Fierce Biotech
- More: Endpoints
|
Everything Else that broke
- FDA chief signals plan to speed new drug trial starts. — Endpoints
- Novo cuts 400 jobs at ex-Catalent Indiana site; Scholar Rock refiles drug linked to the factory. — Endpoints
- Lilly’s Foundayo launch begins April 6 via LillyDirect, widening the immediate read-through from approval to commercial execution. — Reuters
- Noom plans push into peptides beyond weight loss drugs. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Zai Lab and Amgen signed a global clinical collaboration to test DLL3 ADC zocilurtatug pelitecan with IMDELLTRA in ES-SCLC; Amgen will sponsor the Phase 1b study, while Zai retains ownership of zoci. — Business Wire
-
Lupin completes acquisition of VISUfarma. — PR
-
Tanabe Pharma America finalizes RADICAVA transfer to Shionogi. — PR
VC / Private Financings
- StairMed closed an RMB 500M strategic round led by Alibaba, with Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Ventures and Source Code Capital participating. — PR
IPOs / Follow-Ons
- Cyclerion agreed to merge with Korsana Biosciences in an all-stock transaction that will take Korsana public, supported by an oversubscribed ~$380M private financing. — Business Wire
- INOVIO announces proposed public offering. — PR
Things that make you go hmmm ...
Europe’s share of biopharma activity has steadily increased since 2023 — Source: Bain.
Academic Corner- Effectiveness of Ambient AI Scribes. — JAMA
|
|
That’s it for today — may your pills be oral, your holds be lifted, and your tariffs remain draft. See you tomorrow. BioBucks Team
|
|
|
